Organisation paid for research Program year 2025 Source: CMS Open Payments

Associated Retinal Consultants PC

Neither a doctor nor a teaching hospital

Research payments

$4,074,113

706 payments

Through program year 2025, Associated Retinal Consultants PC is reported as receiving $4,074,113 in research payments, across 706 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$278,560	160
2024	Research	$206,455	106
2023	Research	$386,003	114
2022	Research	$604,145	105
2021	Research	$769,756	77
2020	Research	$1,055,902	87
2019	Research	$773,293	57

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $2,843,127 295 payments
Apellis Pharmaceuticals, Inc. $490,459 111 payments
Novartis Pharmaceuticals Corporation $341,053 8 payments
Regeneron Pharmaceuticals, Inc. $148,164 95 payments
F. Hoffmann-La Roche AG $103,070 156 payments
Gilead Sciences, Inc. $98,814 24 payments
AbbVie, Inc. $20,406 8 payments
Ocular Therapeutix, Inc. $12,800 5 payments
Kyowa Kirin, Inc. $11,320 3 payments
EyePoint Pharmaceuticals US, Inc. $4,900 1 payment

Studies the money was for Research payments · program years 2019–2025

Va2 Phiii Yosemite $804,024 52 payments
Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $549,977 42 payments
Port Delivery System for Ranibizumab $367,298 26 payments
Faricimab Dme Long Term Extension Rhone X $293,988 38 payments
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD $279,570 62 payments
A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $275,260 5 payments
Port Delivery System of Ranibizumab Extension Study $230,838 44 payments
Phase 2 of Ro7171009 in Ga $171,885 19 payments
A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $133,762 90 payments
Va2 Phiii Rhine $108,403 23 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.